Trial Profile
Phase 3, Randomized, Double Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 In Patients With Active Psoriatic Arthritis
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2011
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Aug 2011 Planned number of patients changed to 600.
- 09 Aug 2011 New trial record